SCHEMBL1936346

SCHEMBL1936346

O=C(O)c1cccc(-c2ccncc2[N+](=O)[O-])c1

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KMO O15229 2/20 0.55
ERN1 O75460 1/20 0.49
TP53 P04637 1/20 0.48
DDT P30046 1/20 0.46
CASP6 P55212 1/20 0.45
PTGER1 P34995 2/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
ALDH1A1 P00352 1/20 0.44
ROCK2 O75116 1/20 0.44
MAPT P10636 1/20 0.43
CD74 P04233 1/20 0.43
MIF P14174 1/20 0.43
LMNA P02545 1/20 0.42
TSHR P16473 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28433847 0.82 KMT2A (0.46) ALDH1A1MAPTLMNA
SCHEMBL28669741 0.81 ALDH1A1 (0.64) KMOERN1TP53CASP6PTGER1
SCHEMBL20189898 0.81 ALDH1A1 (0.61) ALDH1A1MAPT
SCHEMBL29973546 0.81 ALDH1A1 (0.61) ALDH1A1MAPT
SCHEMBL1936226 0.81 ROCK2 (0.52) ALDH1A1ROCK2MAPT
SCHEMBL1018931 0.77 KMO (0.60) KMODDTPTGER1CYP3A4CYP2C9
SCHEMBL26969164 0.77 PTAFR (0.47) ERN1CYP3A4CYP2C9ALDH1A1ROCK2
SCHEMBL408308 0.76 ERN1 (0.59) KMOERN1TP53CASP6ALDH1A1
SCHEMBL31415060 0.76 ERN1 (0.59) KMOERN1TP53CASP6ALDH1A1
SCHEMBL17461846 0.76 CASP6 (0.53) ERN1TP53CASP6ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230416815-A1 METHOD FOR LABELING NUCLEIC ACID CAMBRIDGE ENTERPRISE LIMITED (GB) 2023-12-28 US disclosed
EP-4211262-A1 METHOD FOR LABELING NUCLEIC ACID Cambridge Enterprise Limited (GB) 2023-07-19 EP disclosed
CN-116323603-A Method for labeling nucleic acids 剑桥实业有限公司 2023-06-23 CN disclosed
WO-2022053718-A1 METHOD FOR LABELING NUCLEIC ACID CAMBRIDGE ENTERPRISE LIMITED (GB) 2022-03-17 WO disclosed
EP-2331502-B1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL MYERS SQUIBB CO (US) 2016-03-02 EP disclosed
EP-2331502-B1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL MYERS SQUIBB CO (US) 2016-03-02 EP disclosed
EP-2545050-B1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL MYERS SQUIBB CO (US) 2014-08-13 EP disclosed
CN-102209711-B Compounds for the treatment of hepatitis C BRISTOL MYERS SQUIBB CO 2014-06-18 CN disclosed
CN-103864783-A Compounds for the Treatment of Hepatitis C BRISTOL MYERS SQUIBB CO 2014-06-18 CN disclosed
US-8536338-B2 Compounds for the treatment of hepatitis C BRISTOL-MYERS SQUIBB COMPANY (US) 2013-09-17 US disclosed
WO-2011112186-A1 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2011-09-15 WO disclosed
EP-2331502-A2 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C Bristol-Myers Squibb Company (US) 2011-06-15 EP disclosed
US-20100184800-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2010-07-22 US disclosed
US-20100184800-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2010-07-22 US disclosed
US-20100184800-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2010-07-22 US disclosed
WO-2010030538-A2 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2010-03-18 WO disclosed
WO-2010030538-A2 COMPOUNDS FOR THE TREATMENT OF HEPATITIS C BRISTOL-MYERS SQUIBB COMPANY (US) 2010-03-18 WO disclosed
US-20100063068-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2010-03-11 US disclosed
US-20100063068-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2010-03-11 US disclosed
US-20100063068-A1 Compounds for the Treatment of Hepatitis C BRISTOL-MYERS SQUIBB COMPANY 2010-03-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230416815-A1 METHOD FOR LABELING NUCLEIC ACID ALKBH1, ALKBH2, NT5C3B KMO 1173/4885ERN1 1348/4885TP53 1342/4885
US-20100063068-A1 Compounds for the Treatment of Hepatitis C HAVCR2, HCCS, SLC10A1 KMO 4328/4885ERN1 718/4885TP53 299/4885
US-20100184800-A1 Compounds for the Treatment of Hepatitis C HAVCR2, HCCS, SLC10A1 KMO 4328/4885ERN1 718/4885TP53 299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.